Suzanne Elvidge

Biotechnology company Eutilex is developing a portfolio of immuno-oncology T cell, chimeric antigen receptor T cell and antibody therapeutics that are now ready for partnering.

Using its proprietary PREDATOR protein engineering platform, Werewolf designs biotherapeutics that are systemically delivered and activated selectively in the tumor microenvironment to recruit a powerful antitumor immune response.

In a major coup for a startup that only turns 6 years old this year, BIND Biosciences has signed a global and exclusive agreement with Amgen, the world's largest independent biotechnology company....

As people live longer, and as global demographics shift toward an older population, age-related eye diseases such as glaucoma and macular degeneration are increasing. The blood-eye barrier is very effective--this is useful in health, protecting such a sensitive organ, but an obstacle in disease as it makes it very hard...

Stallergenes has discovered two biomarkers that could help therapists monitor how well a treatment is working, and also act as measuring points in clinical trials....

A dual-hormone "artificial pancreas" is better at controlling type I diabetes than a simple insulin pump, which could be good news for the two-thirds of diabetics who don't achieve their blood sugar targets with existing treatments....

"Minicells," nanoparticles built from the membranes of mutant bacteria, have safely delivered cancer drugs in their first clinical trial in people with advanced and untreatable cancer, and have shown the first hints of efficacy....

A recently formed privately funded startup, Inform Genomics, is taking the concept of genetic markers and giving it a new twist, Ed Rubenstein, president and CEO, told FierceBiomarkers....